Home
About
Overview
Sharing Data
ORCID
Help
History (1)
Exploiting cancer cell vulnerabilities to develop a combination therapy for ras-driven tumors.
See All Pages
Find People
Find Everything
Login
to edit your profile (add a photo, awards, links to other websites, etc.)
Edit My Profile
My Person List (
0
)
Return to Top
Exploiting cancer cell vulnerabilities to develop a combination therapy for ras-driven tumors.
Exploiting cancer cell vulnerabilities to develop a combination therapy for ras-driven tumors. Cancer Cell. 2011 Sep 13; 20(3):400-13.
View in:
PubMed
subject areas
Animals
Antineoplastic Agents
Antineoplastic Combined Chemotherapy Protocols
Benzoquinones
Carcinoma, Non-Small-Cell Lung
eIF-2 Kinase
Endoplasmic Reticulum
Fluorescent Antibody Technique
Glutathione
HSP90 Heat-Shock Proteins
In Situ Nick-End Labeling
Lactams, Macrocyclic
Mice
Mitochondria
Molecular Targeted Therapy
Nerve Sheath Neoplasms
Oxidative Stress
Polymerase Chain Reaction
Proto-Oncogene Proteins p21(ras)
ras Proteins
Reactive Oxygen Species
RNA Interference
RNA, Small Interfering
Sirolimus
Tumor Cells, Cultured
Tumor Suppressor Protein p53
authors with profiles
Kay Macleod